$130MSeries A, 24 February 2026
Funds clinical development of in-licensed SLTE-1009, with Phase 1 planned for mid-2026.
- Amount
- $130M
- Stage
- Series A
- Announced
- 24 February 2026
- Lead
- RA Capital Management
- Other investors
- Forbion, Foresite Capital
- Use of funds
- Funds clinical development of in-licensed SLTE-1009, with Phase 1 planned for mid-2026.
- Checked
- Announced by the company
- Sources
- Slate Medicines raises $130M Series A for anti-PACAP migraine therapies businesswire.com
Slate Medicines raises $130M Series A for anti-PACAP migraine therapies finsmes.com